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nal-fatty acid binding protein (IFABP; FABP2) is a 15-kDa intracel-
lular protein abundantly present in the cytosol of the small intestinal
(SI) enterocyte. High-fat (HF) feeding of IFABP2/2 mice resulted in
reduced weight gain and fat mass relative to wild-type (WT) mice.
Here, we examined intestinal properties that may underlie the ob-
served lean phenotype of high fat-fed IFABP2/2 mice. No alterations
in fecal lipid content were found, suggesting that the IFABP2/2 mice
are not malabsorbing dietary fat. However, the total excreted fecal
mass, normalized to food intake, was increased for the IFABP2/2
mice relative to WT mice. Moreover, intestinal transit time was more
rapid in the IFABP2/2 mice. IFABP2/2 mice displayed a shortened
average villus length, a thinner muscularis layer, reduced goblet cell
density, and reduced Paneth cell abundance. The number of prolifer-
ating cells in the crypts of IFABP2/2 mice did not differ from that of
WT mice, suggesting that the blunt villi phenotype is not due to
alterations in proliferation. IFABP2/2 mice were observed to have
altered expression of genes and proteins related to intestinal structure,
while immunohistochemical analyses revealed increased staining for
markers of inflammation. Taken together, these studies indicate that
the ablation of IFABP, coupled with high-fat feeding, leads to changes
in gut motility and morphology, which likely contribute to the rela-
tively leaner phenotype occurring at the whole-body level. Thus,
IFABP is likely involved in dietary lipid sensing and signaling,
influencing intestinal motility, intestinal structure, and nutrient ab-
sorption, thereby impacting systemic energy metabolism.
NEW & NOTEWORTHY Intestinal fatty acid binding protein
(IFABP) is thought to be essential for the efficient uptake and
trafficking of dietary fatty acids. In this study, we demonstrate that
high-fat-fed IFABP2/2 mice have an increased fecal output and are
likely malabsorbing other nutrients in addition to lipid. Furthermore,
we observe that the ablation of IFABP leads to marked alterations in
intestinal morphology and secretory cell abundance.
IFABP; intestine; lipid; morphology; nutrition
INTRODUCTION
The small intestine (SI) is the primary site of dietary lipid
absorption, where the absorptive enterocytes are responsible
for processing the hydrolysis products of dietary lipids. Al-
though dietary triacylglycerol (TG) content is particularly high
in Western diets, absorption from the lumen of its hydrolysis
products, fatty acid (FA), and monoacylglycerol (MG), is
highly efficient, with .95% of dietary lipid taken up (13, 21).
Intracellular carrier proteins are thought to be required for
efficient trafficking of these hydrophobic lipid species within
the hydrophilic cytoplasmic milieu, although this has not been
definitively shown. The intestinal-FA-binding protein (IFABP;
FABP2) is a member of the FABP family, a group of 14- to
15-kDa intracellular proteins that are present in high abun-
dance (1–5%) in the cytosol of most tissues (21, 67, 68). Like
other members of the FABP family, IFABP has a high affinity
for long-chain fatty acids (LCFAs) (65), and in vitro studies
have shown that IFABP transfers FAs to membranes via a
collisional mechanism that is typical of most members of the
FABP family (28). Several in vitro and ex vivo studies have
suggested that IFABP is involved in enterocyte uptake of FA
from both the intestinal lumen and the bloodstream (3, 55).
However, a number of studies in animal models lacking IFABP
have found that FA uptake is not impaired (22, 44, 71).
We previously showed that on a 45% Kcal fat high-fat diet
(HFD) IFABP2/2 mice remained lean compared with WT
mice, displaying reduced body wt (BW), but food efficiency
calculations indicated that the observed decrease in BW of the
IFABP2/2 mice could not be fully explained by the decrease in
food intake (22). Since, as noted above, the enterocyte FABPs
have long been thought to be involved in dietary lipid uptake
and assimilation (21), it is tempting to speculate that mice
lacking IFABP might malabsorb lipid, thus explaining their
observed lean phenotype. Fecal lipid content did not vary
between groups, however, suggesting that the IFABP2/2 mice
were not malabsorbing lipid (22). As it is possible that the lipid
content of the 45% Kcal HFD is not sufficient to stress the
absorptive capacity of the small intestinal enterocytes, in the
present studies we examined fecal fat in mice fed a supraphysi-
ological 60% Kcal fat diet. In addition, we determined not only
fecal lipid content, but also the small intestinal localization of
FA absorption along the proximal-to-distal axis, total fecal
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excretion, and the intestinal transit time of mice fed the 45%
Kcal HFD.
During organ collection, it was observed that the intestinal
tissue of the HF-fed IFABP2/2 mice seemed to be more fragile
than that of wild-type (WT) mice. We, therefore, hypothesized
that the ablation of IFABP may lead to alterations in intestinal
structure and, perhaps, inflammation. Thus gene expression,
histological, and immunohistochemical (IHC) analyses were
performed to assess small intestinal integrity and inflammatory
status. Additionally, we assessed small intestine goblet cell
density, since mucus production by the goblet cells is impor-
tant for intestinal integrity (38). We also examined Paneth cell
density, as Paneth cells secrete antimicrobial peptides and
other molecules that regulate cell proliferation and differenti-
ation (16).
The results showed no differences, relative to WT mice, in
the fecal lipid content of IFABP2/2 mice, even when chal-
lenged with the supraphysiological 60% Kcal HFD. Interest-
ingly, however, 45% Kcal HF-fed IFABP2/2 mice were found
to have increased total fecal excretion and reduced energy
absorption, which was explained, at least in part, by a more
rapid intestinal transit rate. Additionally, IFABP2/2 mice were
found to have altered expression of genes encoding intestinal
structural markers and markers of endoplasmic reticulum (ER)
stress, shorter proximal small intestinal villi, a thinner muscu-
laris layer, a reduction in Paneth cell abundance, and a reduced
goblet cell density. Collectively, these changes in the IF-
ABP2/2 intestinal mucosa indicate a heretofore unappreciated
role for IFABP in intestinal motility and integrity, and suggest
that reduced weight gain is secondary to increased fecal ex-
cretion of lipids, and, likely, other nutrients.
EXPERIMENTAL PROCEDURES
Animals and diets. As previously reported, the IFABP2/2 mice
used in this study are a substrain bred by intercrossing of an original
strain of IFABP2/2 mice and are congenic on a C57BL/6J back-
ground (44, 45, 71). C57BL/6J mice from The Jackson Laboratory
(Bar Harbor, ME) were bred as WT controls. Mice were housed two
to three/cage unless specified otherwise, maintained on a 12:12-h
light-dark cycle, and allowed ad libitum access to standard rodent
chow (Purina Laboratory Rodent Diet 5015). At 2 mo of age, male
WT and IFABP2/2 mice were fed either a 45% Kcal fat HFD
(D10080402; Research Diets, New Brunswick, NJ), a 60% Kcal HFD
(D04051705; Research Diets), or a 10% Kcal fat low-fat diet (LFD;
D10080401; Research Diets) as indicated. BW were measured weekly
for a period of 12 wk. Fat mass measurements were taken by MRI
(Echo Medical Systems, Houston, TX) 2–3 days before the start of the
feeding protocol and 2–3 days before euthanasia. The instrument was
calibrated each time according to the manufacturer’s instructions. At
each time point, two measurements were taken for each mouse and
averaged. The Rutgers University Animal Care and Use Committee
approved all animal experiments.
Preparation of tissue and plasma. Mice were fasted for 16 h before
being euthanized unless otherwise stated. At euthanization blood was
drawn; plasma was isolated after centrifugation for 6 min at 4,000
rpm, and stored at 280°C. Epididymal fat pads and livers were
removed, immediately placed on dry ice, and stored at 280°C for
further analysis. The small intestine from the pyloric sphincter to the
ileocecal valve was removed, measured lengthwise, rinsed with 60
mL of ice-cold 0.1 M NaCl, and opened longitudinally. Intestinal
mucosa was scraped with a glass microscope slide into tared tubes on
dry ice and stored at 280°C for future use.
RNA extraction and real-time PCR. Total mRNA was extracted
from small intestinal mucosa and analyzed as previously described
(22, 44). Primer sequences were obtained from Primer Bank (Harvard
Medical School QPCR Primer Database) or as indicated, and are
shown in Table 1. The efficiency of PCR amplifications was analyzed
for all primers to confirm similar amplification efficiency. Real-time
PCRs were performed in triplicate using an Applied Biosystems 7300
instrument. Each reaction contained 80 ng of cDNA, 250 nM of each
primer, and 12.5 mL of SYBR Green Master Mix (Applied Biosys-
tems, Foster City, CA) in a total volume of 25 mL. Relative quanti-
fication of mRNA expression was calculated using the comparative Ct
method, normalized to TATA-binding protein (TBP). Primer se-
quences for the genes that were analyzed are shown in Table 1.






















































F, forward; R, reverse. *, as in (63a). See the text for additional definitions.
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Western blot analysis. Small intestinal mucosa was harvested as
described above and homogenized in 103 volume of PBS pH 7.4 with
0.5% (vol/vol) protease inhibitors (Sigma 8340) on ice with a Potter
Elvejhem homogenizer. Total cytosolic fractions were obtained by
ultracentrifugation (100,000 g, 1 h at 4°C), and protein concentration
was determined by Bradford assay (11). Thirty micrograms of cyto-
solic protein was mixed with an Instant-Bands prestained protein
sample loading buffer in a 2:1 (vol/vol) ratio (EZBiolab, Carmel, IN)
to allow for visualization of total sample protein. Samples were loaded
onto 15% polyacrylamide gels and separated by SDS-PAGE. A
protein standard (catalog no.1610375, Bio-Rad) was loaded to ensure
that the expected bands were present at the appropriate size for each
antibody used. The proteins were transferred onto 0.45-mm nitrocel-
lulose membranes using a semidry transfer system (Bio-Rad) for 1 h
and 45 min at 23 V. Membranes were blocked by incubating in 5%
nonfat dry milk overnight at 4°C, and were incubated with a primary
antibody of either a-LFABP [1:2,000 for 1 h at room temperature
(44)] or a-IFABP (1:10,000 for 1 h at room temperature). Purified
liver FABP (LFABP) or IFABP was used as a positive control,
respectively. For assessing phosphorylated and total eIF2a, mem-
branes were blocked in 5% milk for 1 h at room temperature and then
incubated with either a-phospho(S51)-eIF2a (1:5,000, CST 3597,
Cell Signaling Technology) or a-eIF2a (1:5,000, sc-11386, Santa
Cruz) overnight at 4°C (59, 63a). After thorough washing, blots were
incubated in a-rabbit IgG-horseradish peroxidase conjugate (1:
20,000) for 1 h, and developed by chemiluminescence (Amersham
Biosciences). Protein expression was quantified by densitometric
analysis with LI-COR Image Studio (Lite version 5.2). Target protein
content was normalized to total protein content within a sample.
Fecal lipid content. During the 12-wk high-fat feeding periods,
feces were collected between weeks 10 and 12 of the feeding protocol,
and subsequently dried at 60°C for 3 days. Then, 0.5 g (dry weight)
of feces was dissolved in water overnight, and lipids were extracted
using the Folch method (20). The extracted lipids in 2:1 chloroform/
methanol (vol/vol) were placed in preweighed glass tubes, dried down
completely under a nitrogen stream, and recovered lipid mass was
determined by weight difference. The weight of the extract was
divided by the original dry weight of the feces to determine the
percent fecal lipid.
Fat absorption localization experiment. The protocol described by
Nelson et al. (57) was modified to perform fat absorption localization
experiments. In short, following a 4.5-h fast, mice were gavaged with
8 mCi of [3H]TG in 200 mL olive oil. The mice were anesthetized 1.5
h after the gavage, and the small intestine was excised, rinsed with
0.85% NaCl, and then cut into 2-cm sections. The intestinal sections
were digested overnight in 500 mL of 1 M NaOH at 60°C. The next
day, 300 mL of 1 N HCl was added to quench, and the radioactivity
of each section was measured in a scintillation counter.
Intestinal transit time. Individually housed mice were allowed ad
libitum access to food and water. After 2 h of acclimation, mice were
given 200 mL of 6% carmine red and 0.5% methylcellulose (Sigma-
Aldrich, St. Louis, MO) in PBS by oral gavage. The cages were
inspected every 10 min postgavage, and the time of appearance of the
first red fecal pellet was recorded (37, 56).
Total fecal excretion. Mice were housed two to three/cage. Feces
from each cage were collected every 3–4 days, and subsequently dried
overnight and weighed. The weight of the feces was divided by the
number of mice in the cage, and by the number of days of collection.
To control for differences in food intake, the results for each genotype
were normalized to their respective 24-h food intakes, to generate
values of gram feces excreted per gram consumed per mouse per day.
Bomb calorimetry. Fecal energy content was assessed using a
microbomb calorimeter (Parr) with a benzoic acid standard (23, 48).
Briefly, six fecal pellets were homogenized in 2 mL water to form a
uniform slurry. Fecal samples were then frozen at 280°C. Thawed
samples were lyophilized, and each sample was used to form two
uniform pellets with a pellet press. Each pellet was separately loaded
into the microbomb calorimeter for caloric density assessment. Each
pellet represented one measure per sample, allowing for samples to be
measured in duplicate. Energy absorbed was determined by calculat-
ing the energy ingested from the semipurified HF diet/24 h minus the
energy excreted in the feces/24 h.
Plasma endotoxin analysis. Plasma endotoxin levels were assessed
using a Pierce LAL Chromogenic Endotoxin Quantitation Kit (catalog
no. 88282, Thermo Fisher Scientific), according to the manufacturer’s
instructions. Samples were run in triplicate and averaged to provide a
plasma endotoxin value for each mouse.
FITC-dextran intestinal permeability assay. Intestinal permeability
was assessed by a modified version of the protocol described by
Wotin and Blaut (74). Briefly, after a 6-h fast, mice were orally
gavaged with 150 mL of FITC-dextran (MW 5 4,000; 100 mg/mL;
catalog no. 60842-46-8, Millipore Sigma). Four hours postgavage,
mice were euthanized and whole blood was collected. Serum was
isolated by centrifugation and kept in the dark at room temperature for
30 min before analysis. A standard curve was developed on a 96-well
plate using FITC-dextran concentrations in a range between 100 and
1 mg/mL. Fluorescence intensities of the standards and samples were
then measured using an excitation of 485 nm and emission of 528 nm.
After blank subtraction, sample FITC concentrations were determined
based on the standard curve (in mg/mL).
Histochemical and IHC analyses. Small intestines (SI) were re-
moved as described above. The first sixth of the SI, representing the
proximal SI, was isolated, rinsed with a cold 0.85% sodium chloride
solution, opened longitudinally, Swiss rolled, and fixed overnight at
4°C in 3% paraformaldehyde (PFA) and 2% sucrose in phosphate
buffered saline. Tissues were then embedded in paraffin. For initial
histological analysis, 5-mm intestinal tissue sections were stained with
hematoxylin and eosin (H&E; Rutgers Pathology Services, Piscat-
away, NJ). Average villus length was assessed by dividing H&E-
stained Swiss roll sections into 5 quadrants and measuring 20 villi per
quadrant, for a total of 100 villi measured per animal. To assess
average muscularis thickness, 80 separate measurements were re-
corded for each animal. These were averaged to provide a value
specific to that mouse. Goblet cells were enumerated using periodic
acid-Schiff (PAS)/Alcian blue, which stained acidic and neutral mu-
cins, respectively. Goblet cell count was normalized to villus length,
allowing for goblet cell density to be determined. For the visualization
of Paneth cells, phloxine-tartrazine staining was performed (Lend-
rum’s stain kit; catalog no. ES9540, Thermo Fisher Scientific). For
IHC studies, 5-mm intestinal sections were deparaffinized, rehydrated,
and blocked with 100% normal goat serum at room temperature for 2
h. The tissue sections were then incubated overnight at 4°C with a
primary rabbit polyclonal cyclooxygenase (COX)-2 antibody (1:500,
Abcam, Cambridge, MA), mucin 2 antibody (1:100, Abcam), induc-
ible nitric oxide synthase (iNOS) antibody (1:100, Abcam), claudin 2
antibody (1:200, Abcam), claudin 5 antibody (1:200, Abcam), mouse
polyclonal MCP1 antibody (1:200, Abcam), or a nonspecific isotype
control. Tissue sections were then incubated for 30 min with a either
a biotinylated goat anti-rabbit secondary antibody (1:10,000, Vector
Laboratories, Burlingame, CA) or biotinylated horse anti-mouse sec-
ondary antibody (1:10,000, Vector Laboratories). Antibody binding
was visualized using a DAB Peroxidase Substrate Kit (Vector Labo-
ratories). Tissue sections were scanned using a VS120-L100 Olympus
virtual slide microscope (Waltham, MA).
Bromodeoxyuridine assays. Proliferation was assessed by measur-
ing the incorporation of bromodeoxyuridine (BrdU). Mice were in-
jected with 200 mL of BrdU (BD Biosciences) intraperitoneally 2 or
48 h before euthanasia. SI were removed, Swiss rolled, and fixed
overnight at 4°C in a 3% PFA solution. IHC staining for BrdU was
then performed using an anti-BrdU antibody (1:400; BD Biosciences).
Tissue sections were then incubated for 30 min with a biotinylated
horse anti-mouse secondary antibody (1:10,000, Vector Laboratories,
Burlingame, CA). Antibody binding was visualized using a DAB
Peroxidase Substrate Kit (Vector Laboratories).
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Statistical analysis. All group data are shown as average 6 SE.
Statistical comparisons were determined between genotypes on the
same diet using a two-sided Student’s t test. Differences were con-
sidered significant for P , 0.05.
RESULTS
IFABP2/2 mice remain lean on supraphysiological HFD. At
8 wk of age, before the start of HF feeding, IFABP2/2 and WT
mice had similar BW, fat mass, and fat free mass (data not
shown). As previously demonstrated (22), after 12 wk of 45%
Kcal HF feeding, IFABP2/2 mice gain less weight and remain
lean compared with WT mice (Fig. 1). When challenged with
a supraphysiological 60% Kcal HFD for 12 wk, the same
pattern is observed, with IFABP2/2 mice still gaining less
weight and remaining leaner than WT mice (Fig. 1).
Ablation of IFABP does not cause compensatory upregula-
tion of LFABP in HF diet-fed mice. The expression of LFABP
in response to ablation of IFABP was assessed after 12 wk of
45% Kcal fat HF feeding. As was observed previously for mice
fed a LF chow diet, IFABP2/2 mice do not have increased
LFABP mRNA or protein levels relative to WT mice (Fig. 1,
C and D). Additionally, we found no compensatory upregula-
tion of the distal small intestinal FABP, ileal FABP (ILBP,
FABP6); other FABPs that are not typically expressed within
the SI were also not observed in either WT or IFABP2/2
intestine from the HF-fed mice (Fig. 1E).
Mice lacking IFABP have increased fecal mass, reduced
energy absorption, and faster intestinal transit. Consistent with
previous observations, IFABP2/2 mice do not appear to mal-
absorb lipid on a 45% Kcal HF diet, based on fecal fat content
(Fig. 2A). Similarly, in mice challenged with the very high
60% Kcal fat diet, no differences in fecal fat content were
noted between IFABP2/2 and WT mice (Fig. 2A). Addition-
ally, no shift in 3H-labeled FA uptake along the proximal to
distal axis of the small intestine was observed in mice chal-
lenged with the 45% Kcal HFD (Fig. 2B). Interestingly, how-
ever, analysis of total fecal mass showed that 45% Kcal HF-fed
IFABP2/2 mice have a significant increase in total fecal
excretion, controlling for total food intake (Fig. 2C). Further-
more, the IFABP2/2 mice had significantly shorter intestinal
transit times, indicating that nutrients moved from the mouth to
anus more rapidly (Fig. 2D). Together these data imply that the
IFABPV2/2 mice are, indeed, absorbing less lipid than WT
mice. Moreover, they may be absorbing less of other nutrients
as well, as evidenced by the increase in fecal mass without a
change in fecal fat content. This was confirmed by bomb
calorimetric assessment of fecal caloric density, which revealed
that there were no differences between WT and IFABP2/2
Fig. 1. Body weight, fat mass, and small intestine fatty acid binding protein (FABP) expression for wild-type (WT; circles) and intestinal FABP null (IFABP2/2;
squares) mice after 12 wk of high fat (HF) feeding. A: body weights on 45% Kcal fat (n 5 10) or 60% Kcal fat high-fat diet (HFD; n 5 6–7); B: body fat
percentage on 45% Kcal fat (n 5 10) or 60% Kcal fat HFD (n 5 6–7). C: relative gene expression of FABP family members (n 5 5–12). D, top: Western blot
membranes blotting for either liver FABP (LFABP; left) or intestinal FABP (IFABP; right); bottom: total protein content of the Western membranes. E: relative
protein levels of IFABP or LFABP (n 5 8). Purified LFABP (pLF) and purified IFABP (pIF) were loaded as positive controls for the Western blots.
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mice (Fig. 2E). Indeed, since IFABP2/2 mice ingest fewer
calories per day and excrete the same amount of calories per
day in their feces, they have a net reduction in energy that is
absorbed from the diet compared with their WT counterparts.
The rapid transit time, increased fecal excretion, and reduced
energy absorption suggest that IFABP may play a role in the
regulation of intestinal motility and, hence, in lipid and nutrient
absorption.
Alterations in SI morphology and structure. IFABP2/2
mice were found to have a 7% shorter SI length compared
with WT mice (Fig. 3A) (P , 0.05); however when normal-
ized to average BW, IFABP2/2 mice have an 8% longer SI
for their size, relative to WT mice (Fig. 3B) (P , 0.05).
Analysis of H&E-stained sections revealed that the proximal
SI villi of HF-fed IFABP2/2 mice are 39% shorter than the
villi of WT mice (Fig. 4, A–C) (P , 0.01). In addition to
having shortened villi, IFABP2/2 mice were also found to
have a thinner muscularis layer (Fig. 4, A, B, and D). Alcian
blue/PAS staining revealed that IFABP2/2 mice have sig-
nificantly fewer SI goblet cells than WT mice, and when
normalized to average villus length, a reduced goblet cell
density (Fig. 4, E–G) (P , 0.01). In addition to having a
reduced goblet cell density, Lendrum’s staining revealed
that the other major secretory cells of the SI, Paneth cells,
were also in lower abundance in IFABP2/2 mice (Fig. 4, H
and I).
Mice null for IFABP have increased incidence of cell death
in proximal SI. While both goblet cell staining and Paneth cell
staining revealed a reduced amount of those specific cell types,
a proliferation assay where mice were gavged with BrdU 2 h
before excision indicated that the amount of proliferating cells
in the crypts was not significantly different between IFABP2/2
mice and WT mice (Fig. 5, A–C). However, 48 h after gavage
with BrdU, IFABP2/2 mice were found to have fewer BrdU-
positive cells in their villi compared with WT mice (Fig. 5,
D–F). While the whole villus of the IFABP2/2 stained posi-
tively for BrdU, WT mice displayed unstained cells toward the
tips of their villi, with the middle and lower portions of their
villi staining positively for BrdU (Fig. 5, D and E). The
positive staining in tissue collected from mice 2 h post-BrdU is
considered representative of actively proliferating cells, while
the positive staining associated with tissue collected from mice
Fig. 2. Fecal lipid content, fat absorption localization, total fecal output, and intestinal transit times wild-type (WT; circles) and intestinal fatty acid binding
protein (FABP) null (IFABP2/2; squares) mice after 12 wk of high fat (HF) feeding. A: fecal lipid percentage from 45% Kcal HF-fed WT and IFABP2/2 mice
(n 5 8) and fecal lipid percentage from 60% Kcal HF-fed WT and IFABP2/2 mice (n 5 6). B: localization of intestinal lipid absorption 1.5 h after oral gavage
of [3H] triacylglycerol (TG) in olive oil in mice fed the 45% Kcal HFD (n 5 6–8). C: daily food intake and fecal excretion in WT and IFABP2/2 mice fed the
45% Kcal high-fat diet (HFD) and fecal excretion normalized for intake (n 5 6). D: intestinal transit time in WT and IFABP2/2 mice fed the 45% Kcal HFD
(n 5 8–13). E: daily energy intake and energy absorption (accounting for energy excretion) in WT and IFABP2/2 mice fed the 45% Kcal HFD (n 5 8).
Fig. 3. Average length of small intestine (SI) in wild-type (WT; circles) and
intestinal fatty acid binding protein (FABP) null (IFABP2/2; squares) mice that
have been fed a 45% Kcal high-fat diet (HFD) for 12 wk. A: average SI length in
high fat (HF)-fed WT and IFABP2/2 mice. B: average SI length normalized to the
average body mass in HF-fed WT and IFABP2/2 mice (n 5 12).
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48 h postgavage is considered to be more representative of cell
migration up the villus tips.
Mice null for IFABP have increased intestinal permeability.
Intestinal permeability was assessed in two ways. Plasma
endotoxin (lipopolysaccharide or LPS) levels were analyzed as
an indirect measure of intestinal permeability, and it was found
that HF-fed IFABP2/2 mice have similar plasma endotoxin
levels as their obese WT counterparts (data not shown). A
direct assessment of permeability using a FITC-dextran assay
demonstrated that IFABP2/2 mice have increased intestinal
permeability relative to WT mice (Fig. 6A).
Alterations in expression of tight junction genes, markers of
inflammation, and markers of ER stress. IFABP2/2 mice have
a 56% increased expression of claudin 2, a gene encoding a
pore-forming tight junction (TJ) protein, and 57% decreased
expression of claudin 5, a gene encoding a tightening TJ
protein (Fig. 6B) (P , 0.05). Both increased claudin 2 expres-
sion and decreased claudin 5 expression are associated with
increased intestinal permeability. At the level of gene expres-
sion, it was found that IFABP2/2 mice have increased expres-
sion of caspase 3 (P , 0.01) and activating transcription factor
6 (ATF6) (P , 0.05), both of which are markers of ER stress
and apoptosis (Fig. 6C). Interestingly, while the abundance of
mucin-producing goblet cells was significantly lower in the SI
of IFABP2/2 mice, gene expression for mucin 2, the most
abundant mucin produced by small intestinal goblet cells, was
similar to that of WT mice (Fig. 6C). However, IHC analysis
of mucin 2 showed reduced staining in IFABP2/2 mice,
indicating a reduced abundance of mucin 2 protein (Fig. 7).
Additionally, in agreement with the directional changes ob-
served at the level of gene expression, claudin 2 staining was
increased and claudin 5 staining was decreased in the HF-fed
IFABP2/2 mice (Fig. 7). Staining for monocyte chemoattrac-
tant protein 1 (MCP1), a marker of inflammation, ER stress,
and immune cell infiltration, was increased in IFABP2/2 mice
(Fig. 8). Furthermore, IHC staining for inducible nitric oxide
synthase (iNOS) and cyclooxygenase 2 (COX2), which are
also markers of inflammation and ER stress, showed increased
expression in IFABP2/2 mice compared with WT mice (Fig.
8). However, when the phosphorylation of eukaryotic initiation
factor 2a (eIF2a), another marker of ER stress, was assessed,
no difference was found between groups (Fig. 8). IgG controls
were negative for each antibody that was used.
Phenotypes observed in HF-fed IFABP2/2 mice are largely
but not entirely dependent on dietary fat content. Since the
above-described phenotypes found in the IFABP2/2 mice were
found in HFD-fed animals, we wondered whether the effects
were due solely to the ablation of IFABP, or whether the
chronic exposure to a HF challenge was needed to develop
the blunt villus and other phenotypic changes observed in the
IFABP2/2 mouse. Thus a cohort of IFABP2/2 and WT mice
were fed a matched 10% Kcal fat LF diet for 12 wk beginning
at 8 wk of age. LF-fed IFABP2/2 mice were found to have an
average villus length that was 17% shorter than their WT
Fig. 4. Small intestinal (SI) structure in 45% Kcal high fat (HF)-fed wild type (WT; circles) and intestinal fatty acid binding protein (FABP) null (IFABP2/2;
squares) mice. A and B: hematoxylin and eosin (H&E)-stained SI tissue sections (36.6). C: average villus length of proximal SI villi. D: average muscularis
thickness in proximal SI. E and F: periodic acid-Schiff (PAS)/Alcian blue used to visualize goblet cells (38). The arrows point to positive staining for mucins.
G: average goblet cell density in proximal SI. H and I: Lendrum’s stain used to visualize secretory Paneth cells (360). The arrows point to positive staining for
the acidophilic granules of the Paneth cells (n 5 3).
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counterparts (P , 0.01) (Fig. 9A), about half the decrease
found under HF feeding (Fig. 4). No reduction in muscularis
thickness was observed in the LF-fed IFABP2/2 compared
with the WT group (Fig. 9B). As expected for mice that have
shorter villi, IFABP2/2 mice had fewer total goblet cells (P ,
0.05); however, when normalized to the average villus length,
no significant difference in goblet cell density between groups
was found (Fig. 9, C and D). In addition to histological
assessments, total fecal output and intestinal transit time were
determined for the LF-fed IFABP2/2 and WT mice. Unlike
their HF-fed counterparts, no differences were observed in
total fecal output or intestinal transit time (Fig. 9, E and F).
DISCUSSION
Proximal intestinal enterocytes express both IFABP and
LFABP. In humans, IFABP is less abundant than LFABP (47,
62); however, mice express similar levels of LFABP and
IFABP within the SI mucosa (6, 47, 62). While no compensa-
tory upregulation of LFABP was observed in chow-fed IFABP
null mouse intestine (44), we wondered whether a HFD might
lead to increased LFABP expression. We found, however, that
as with the chow-fed mice, HF-fed IFABP2/2 mice did not
have a compensatory increase in LFABP gene expression or
protein abundance, and no change in the gene expression of the
distal SI FABP, ileal-FABP (ILBP; FABP6) was observed.
Thus the phenotypic changes observed in the IFABP2/2 mice
appear to be independent of the abundance of other FABPs,
further supporting the independent and distinct roles of the
proximal SI FABPs, IFABP, and LFABP, in intestinal and
whole body homeostasis.
Notably, total fecal mass per gram of food intake of HF-fed
IFABP2/2 mice was markedly greater than that of the WT
mice. This increase in fecal output in the absence of changes in
lipid concentration was unanticipated and suggested that intes-
tinal transit time might be impacted by IFABP2/2 deletion.
Indeed, we found that the HF-fed IFABP2/2 mice had signif-
icantly more rapid intestinal transit, relative to WT mice. Thus
the enhanced intestinal transit and increased fecal excretion
suggests that IFABP2/2 mice are in fact malabsorbing nutri-
ents in general, including lipid. Indeed, bomb calorimetric
assessments revealed reduced energy absorption in HF-fed
IFABP2/2 mice. It is therefore likely that the reduced energy
absorption coupled with decreased food intake explain why the
IFABP2/2 mice remain lean on both HF and very HF diets.
The alterations in total fecal output and intestinal transit time
appear to be absent in LF-fed IFABP2/2 mice, suggesting that
the ablation of IFABP in addition to a HF challenge are
necessary for these physiological alterations to be observed.
Ironically, these studies support the prevailing hypothesis that
IFABP is involved in efficient dietary lipid assimilation, al-
though the present results indicate that the effects of IFABP
ablation are not related to specific alterations in intestinal lipid
processing.
The vagus nerve (VN) plays a major role in the regulation of
GI motility. Vagal afferent neurons express cannabinoid recep-
tor 1 (CB1R), which is part of the complex endocannabinoid
system (ECS), a signaling system that is known to play a large
role in the regulation of food intake (17, 31, 61). Several
FABPs have been shown to bind ECs, and appear to be
involved in the regulation of intracellular EC levels (32, 33,
45). Interestingly, we showed that the IFABP2/2 mice had
somewhat lower mucosal levels of 2-arachidinoylglycerol (2-
AG) (22), an EC that acts as a full agonist of CB1R (17, 72).
Activation of CB1R by receptor agonists has been shown to
Fig. 5. Bromodeoxyuridine (BrdU) staining
for 2 or 48 h in the small intestinal crypts
and villi of wild-type (WT; circles) and in-
testinal fatty acid binding protein (FABP)
null (IFABP2/2; squares) mice fed a 45%
Kcal high-fat diet (HFD) for 12 wk. A and B:
small intestinal sections from mice 2 h post-
BrdU injection stained with anti-BrdU (320).
Arrows point to positive staining. C: quan-
tification of 2 h BrdU-positive cells and total
cells in the crypt. Fifty crypts were assessed
per animal (n 5 3). D and E: small intestinal
sections from mice 48 h post-BrdU injection
stained with anti-BrdU (34). F: quantifica-
tion of 48 h BrdU-positive and total cells in
the villus. Fifteen villi were assessed per
animal (n 5 3).
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decrease intestinal motility in rodent models, while antagonism
leads to more rapid intestinal transit (25, 30, 66, 77). Thus in
IFABP2/2 mice the observed increase in intestinal motility
may be secondary to altered vagal tone caused by reduced
CB1R activation, as a result of lower mucosal EC levels.
It is interesting to note that the shorter villi may also
contribute to the observed more rapid intestinal transit rates.
Villus length decreases from the duodenum to the ileum,
allowing for peristaltic contractions to more rapidly move
intestinal contents as they descend (9), while still allowing for
the efficient absorption of dietary nutrients (21). Shorter prox-
imal intestinal villi in IFABP2/2 mice small intestine would
provide less resistance for passing luminal contents, allowing
them to more rapidly traverse the GI tract. Thus, the shorter
villi may explain, in part, the leanness of HF fed IFABP2/2
mice, with more rapid intestinal motility leaving less time and
less surface area for efficient nutrient absorption.
It was found that the muscularis layer of the proximal SI is
thinner in HF-fed IFABP2/2 mice, which may explain, in part,
the above-noted fragility of the SI. Additionally, the shorter
average villus length of IFABP2/2 mice suggests that there is
less surface area for TJ and adherens junction (AJ) interactions.
We initially hypothesized that the shorter villi might be a result
of reduced crypt cell proliferation. However, mice injected
with BrdU 2 h before tissue collection revealed that both
groups have comparable levels of BrdU-positive cells in their
crypts. Instead, it is likely that the blunt villus phenotype is due
to enhanced cell death, since samples acquired from mice 48 h
after BrdU injection demonstrated that IFABP2/2 mice had
significantly fewer BrdU-positive cells present in their villi
compared with WT mice. It is possible that the IFABP2/2 SI
cells are susceptible to ER stress-induced apoptosis (34), as
discussed further below.
Some of the whole body and SI morphological phenotypes
observed in the IFABP2/2 mice are similar to that of peptide
transporter 1 knockout (PEPT12/2) mice. For example, HF-fed
mice lacking PEPT are also resistant to diet-induced obesity,
displaying reduced food intake and reduced energy absorption
(43). The authors found that HF-fed, but not LF-fed,
PEPT12/2 mice had a blunt villus phenotype and longer SI
compared with their WT counterparts (43). The authors hy-
pothesized that PEPT12/2 mice fail to increase villus length in
response to chronic HF feeding, and that the increased length
of the SI was partially compensating for the lack of response in
proximal SI mucosal mass. Similarly, HF-fed IFABP2/2 mice
display both a blunt villus phenotype and an increase in SI length
when normalized to body weight. While LF-fed IFABP2/2
mice also have shorter villi than LF-fed WT mice, the differ-
ence between LF fed IFABP2/2 and LF-fed WT mice is not as
dramatic as the difference between HF-fed IFABP2/2 and HF
WT mice. In addition to the increased cell death that is
observed in the IFABP2/2 villi, it is possible that the
IFABP2/2 mice also have a reduced capacity to increase villus
length in response to chronic HF feeding.
Overall, the shorter length of the IFABP2/2 mucosal villi
would appear to have important implications for intestinal
transit, nutrient absorption, and intestinal integrity. Others have
reported that the villus length of IFABP2/2 mice maintained
on a LF chow diet did not differ from that of their WT
counterparts (1), while we found a small but significant de-
crease, relative to WT, on a semipurified 10% Kcal LF diet,
and a large decrease in villus length on the 45% kcal HF diet.
Over the past few years, it has become evident that diets rich
in lipids, especially saturated fats, lead to alterations in intes-
tinal structure and physiology (69). Thus the IFABP2/2 mice
may be more sensitive to the effects of lipid-rich diets, leading
to more drastic villus morphological responses to chronic HF
feeding. The differences in the observed villus length in re-
sponse to different diets could also be due to alterations in the
composition of the gut microbiota, which play a role in shap-
ing, and are shaped by, the environment within the intestinal
lumen. It has been demonstrated that HF feeding can induce
intestinal dysbiosis, leading to pathophysiological changes that
include chronic low-grade inflammation, impaired mucus pro-
duction, and altered expression of TJ proteins (69). Differences
in the villus length phenotype of chow-fed IFABP2/2 mice
compared with our LF-fed IFABP2/2 mice may also be due to
the fact that semipurified diets differ from standard chow diets
in fiber quality (1, 14, 22). Many LF and HF semipurified diets
use cellulose, an insoluble fiber, as the sole source of dietary
Fig. 6. Assessment of small intestinal structure and inflammation. Serum
FITC-dextran levels and relative quantitation of mRNA expression of relevant
genes in wild-type (WT; circles) and intestinal fatty acid binding protein
(FABP) null (IFABP2/2; squares) mice fed a 45% Kcal high-fat diet (HFD) for
12 wk. A: serum FITC-dextran levels in mice 4 h after gavage (n 5 8). B:
structure-related genes. C: inflammation-related genes (n 5 8–12).
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fiber (14). Standard chow, by contrast, also contains soluble
fiber, which is able to be metabolized for energy by the
microbiome (14). A chronic lack of soluble fiber appears to
influence the morphology and structure of the GI tract, leading
to reduced colon length, colon weight, and cecum weight (14).
Thus it is possible that the previously reported absence of changes
observed in the intestinal morphology of chow-fed IFABP2/2
mice, relative to the present changes observed in the intestinal
morphology of IFABP2/2 mice fed semipurified LF and HF
diets, may also be due to difference in soluble fiber content.
It has been reported that HF-fed obese mice have elevated
levels of plasma endotoxin, a bacterial component that passes
from the intestinal lumen into the circulation when there is
increased intestinal permeability (12, 39, 54). Interestingly,
we found that although the 45% Kcal HF-fed IFABP2/2 are
leaner than their WT counterparts, they have similar levels
of plasma endotoxin. In fact, both the IFABP2/2 mice and
WT mice have plasma endotoxin levels that are similar to
those that have been observed in mouse models of diet-
induced obesity (39), suggesting that the IFABP2/2 mice,
although lean, may experience increased intestinal permea-
bility in response to chronic HF feeding. As a more direct
assessment of intestinal permeability, FITC-dextran levels
were significantly higher in IFABP2/2 mice, supporting the
possibility of increased intestinal permeability. Together
with the alterations found in TJ-related gene expression
levels, it is likely that increased permeability contributes to
the intestinal fragility phenotype of the IFABP2/2 mouse.
Among the TJ proteins of the GI tract, claudins constitute
the major transmembrane component (4, 46). In the IFABP2/2
Fig. 7. Assessment of proteins related to
small intestinal structure in 45% Kcal fat
high fat (HF)-fed wild-type (WT) and intes-
tinal fatty acid binding protein (FABP) null
(IFABP2/2) mice. A–F: proximal small in-
testine sections stained with either anti-mu-
cin 2 (MUC2), anti-claudin 2, or anti-claudin
5 antibodies. Arrows point to positive stain-
ing (n 5 3).
Fig. 8. Assessment of proteins related to small intestinal inflammation and endoplasmic reticulum (ER) stress in 45% Kcal fat high fat (HF)-fed wild-type (WT;
circles) and intestinal fatty acid binding protein (FABP) null (IFABP2/2; squares) mice. A–F: proximal small intestine sections stained with either
anti-cyclooxygenase (COX) 2, anti-inducible nitric oxide synthase (iNOS), or anti-monocytechemoattractant protein (MCP) 1 antibodies. Arrows point to positive
staining (n 5 3). G: relative quantification of phosphorylated eukaryotic initiation factor 2a (eIF2a) normalized to total eIF2a (n 5 6).
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mucosa, we found increased expression of the channel-forming
claudin 2 and decreased expression of the barrier-forming
claudin, claudin 5. These same directional changes were ob-
served with IHC staining. These changes are associated with a
“leaky gut” phenotype (2, 19, 49, 78), which may partly
explain why the IFABP2/2 mice have increased intestinal
permeability. Interestingly, this pattern of gene expression has
been observed in samples obtained from patients with Crohn’s
disease, an inflammatory bowel disease in which the integrity
of the SI is compromised (4, 78). Indeed, there is evidence that
FABPs present in the SI change their expression pattern in
celiac disease, another GI-related disease that involves chronic
inflammation (10) and in which damaged villi cause a variety
of symptoms, some of which are related to nutrient malabsorp-
tion (70). In intestinal mucosa from celiac disease patients,
both IFABP and LFABP appear to be expressed not only in
cells of the remnant epithelium but also within the hyperpro-
liferative crypts, where FABPs are typically not expressed. It is
possible that abnormal FABP expression, such as a lack of
IFABP expression or induced expression of FABPs in the
crypts, may be a common phenotype of GI-related disorders
that include altered intestinal morphology, structure, and the
overall leaky gut phenomenon.
It should be noted that dysbiosis-induced inflammation may
not easily occur in mice that have more rapid intestinal transit.
Early studies in which intestinal motor activity was assessed in
the context of SI bacterial clearance demonstrated that the
action of peristalsis is the primary line of defense against
abnormal bacterial colonization of the SI (60). Thus it is
possible that the rapid intestinal transit time of the IFABP2/2
mice may be a compensatory response to the alterations oc-
curring in their SI structure and morphology that would nor-
mally make them more susceptible to the induction of inflam-
mation.
Secretory goblet cells along the GI tract secrete mucus that
acts as an initial defensive barrier, providing protection from
physical and chemical challenges (7, 18, 38, 40, 52). Addition-
ally, it has been demonstrated that chronic inflammation of the
GI tract can result in depletion of goblet cells, leading to
alterations of the not only the mucus layer but intestinal
morphology and structure as well (38, 40, 52). The reduced
goblet cell density of the IFABP2/2 mucosa implies that there
is a reduced or altered mucus layer, which in turn may
contribute to the fragility of IFABP2/2 mice SI. Nevertheless,
it should be noted that while reductions of both goblet cell
number and mucin 2 protein levels were observed in the SI of
IFABP2/2 mice, mucosal mucin 2 and mucin 3 gene expres-
sion did not differ between IFABP2/2 mice and WT mice. It is
known that highly secretory cells, such as goblet cells, are very
sensitive to the deleterious effects of chronic ER stress (34,
35). Additionally, iNOS, COX2, and MCP1 are known to be
markers of ER stress, with increased expression and abundance
being observed in chronic ER stress responses (15, 24, 27, 29,
41, 42, 64, 75, 76). Thus the maintenance of mucin 2 and
mucin 3 gene expression in conjunction with decreased goblet
cell density, reduced mucin 2 staining, and increased iNOS,
COX2, and MCP1 staining in the SI of IFABP2/2 mice
suggest that ER stress may play a role in the development of
the HF-fed IFABP2/2 intestinal phenotypes. The upregulated
expression of ATF6 and caspase 3, both of which are markers
of ER stress and apoptosis (34, 35), further supports this
suggestion. Additionally, reduced Paneth cells were also found
in the SI of HF-fed IFABP2/2 mice; these hypersecretory cells,
which secrete an array of antimicrobial peptides, are known to
be particularly sensitive to ER stress (16, 34). Despite these
alterations, it is also important to note that the expression
of CCAAT-enhancer-binding protein homologous protein
(Chop), spliced X-box-binding protein1 (Xbp1s), and enhanced
phosphorylated eIF2a, which are also markers of ER stress and
its induction, were not elevated in the IFABP2/2 mucosa (34,
35), suggesting that if ER stress is playing a role in the
phenotypes observed in the IFABP2/2 mice, it may not be a
major role. However, it is important to mention that the mice
assessed in these studies were fasted for 16 h before tissue
collection. ER stress is influenced by circadian cycling (5, 50,
51), so it is possible that more robust ER stress-related pheno-
types in IFABP2/2 mice may be observed at different ages or
in response to different fasting challenges.
Fig. 9. Small intestinal phenotype assessments in 10% Kcal fat
high fat (HF)-fed wild-type (WT; circles) and intestinal fatty
acid binding protein (FABP) null (IFABP2/2; squares) mice. A:
average villus length (n 5 3). B: average muscularis thickness
(n 5 3). C: total villus goblet cells (n 5 3). D: average goblet
cell density (n 5 3). E: assessment of total fecal excretion
normalized to average food intake (n 5 5). F: assessment of
intestinal transit time (n 5 10–12).
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It is possible that the ablation of IFABP may make the
intestinal epithelial cells more susceptible to FA-induced lipo-
toxicity, which could subsequently promote ER stress. Inter-
estingly, some of the phenotypes that are observed in HF
IFABP2/2 mice have also been observed in mice with an
intestine-specific ablation of X-box-binding protein1 (XBP1).
XBP1 is a transcription factor that is essential to the unfolded
protein response (UPR) that is a hallmark of the physiological
attempt to resolve ER stress (36). Intestine-specific XBP12/2
mice were found to have almost no Paneth cells, and a
reduction in goblet cell abundance (36). As mentioned above,
since IFABP2/2 mice do not appear to have reduced crypt cell
proliferation, it is tempting to speculate that the blunt villus
phenotype and alterations in goblet cell and Paneth cell popu-
lations might be due, instead, to enhanced apoptosis that may
occur via the ER stress response. Indeed, the 48-h BrdU
staining results suggest that IFABP2/2 mice have enhanced
cell death; this may be due to ER stress-related apoptosis, ER
stress-independent apoptosis, or anoikis (cell shedding) (8, 73).
The present results indicate that IFABP is not specifically
essential for dietary lipid assimilation. Rather, it appears to be
functioning, perhaps via EC or FA binding, to regulate intra-
cellular signaling and/or transcriptional programing. Indeed,
some members of the FABP family have been shown to
interact with nuclear hormone receptors (NHRs) such as per-
oxisome-proliferator activated receptors (PPARs) and hepato-
cyte nuclear factors (HNFs) (26, 53, 58, 63). Taken together,
the changes observed in IFABP2/2 mouse proximal SI mor-
phology, structural genes, propensity toward increased inflam-
mation, markers of ER stress, Paneth cell abundance, and
goblet cell density are likely indicative of reduced structural
integrity. Thus these studies suggest that IFABP likely plays a
role in dietary lipid sensing and signaling, modulating intesti-
nal structure and the capacity for nutrient absorption, thereby
subsequently altering whole-body energy metabolism.
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